Recovery in sight 1H13 earnings slightly above estimates Earnings growth resumes with FY13F-15F CAGR of 12% on new markets, new incentive arrangements and capacity expansion Valuation is attractive at 10x 1-yr forward rolling PE which is 0.6SD below historical average Reinstating coverage with BUY, HK$15.70 TP